SOLO-1 Phase 3 trial

December 5, 2019December 9, 2019

China OKs Lynparza as Maintenance Therapy for Advanced Ovarian Cancers with BRCA Mutations

News

Oral Lynparza (olaparib) has been approved in China as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer who responded to initial platinum-based chemotherapy, AstraZeneca and Merck (known as MSD ... Read more

July 31, 2019August 26, 2019

NHS England to Cover Lynparza Earlier in Advanced OC Treatment

News

Maintenance treatment with Lynparza (olaparib) is now recommended after response to the first round of platinum-based chemotherapy in women with advanced ovarian cancer on England’s National Health Service (NHS). The decision by ... Read more

July 8, 2019

Lynparza Approved in Japan as First-Line Maintenance Therapy for Advanced OC

News

Lynparza (olaparib) has been approved in Japan as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer that is responding, partially or completely, to their initial chemotherapy, AstraZeneca and Merck (known ... Read more

May 8, 2019

Lynparza Recommended for Approval in Europe for BRCA-mutated Advanced OC

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended that Lynparza (olaparib) be approved as a first-line maintenance therapy for women with ... Read more

January 7, 2019

BRACAnalysis CDx Approved in US as Companion Diagnostic Test for First-line Lynparza Treatment

News

Myriad Genetics‘ BRACAnalysis CDx has been approved by the U.S. Food and Drug Administration as a companion diagnostic test to identify women with ovarian cancer eligible for first-line maintenance treatment with Lynparza (olaparib). ... Read more

January 4, 2019

Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer

News

Women with BRCA-mutated advanced ovarian cancer living in the United States can now receive Lynparza (olaparib), developed by AstraZeneca and Merck, as a maintenance treatment for their partial or complete response to first-line ... Read more

October 24, 2018

Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows

News

Ovarian cancer patients with BRCA mutations who received Lynparza (olaparib) maintenance treatment after first-line platinum-based chemotherapy lived three years longer without signs of disease worsening than patients who received a ... Read more

July 27, 2018

Lynparza Maintenance for Ovarian Cancer Takes No Toll on Quality of Life, Study Shows

News

Ovarian cancer patients who responded to platinum-based chemotherapy after failing at least one prior treatment may take Lynparza (olaparib) as maintenance therapy without worrying about their quality of life, a new study ... Read more